M. Hanafiah, K. Groeger, J. Flaxman, A. D. Wiersma, and S. T. , Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence, Hepatology, vol.29, issue.Suppl, pp.1333-1342, 2013.
DOI : 10.1002/hep.26141

R. Flisiak, J. Jaroszewicz, and A. Parfieniuk-kowerda, Emerging treatments for hepatitis C, Expert Opinion on Emerging Drugs, vol.56, issue.1, pp.461-475, 2013.
DOI : 10.1016/S0168-8278(13)60801-6

I. Gentile, Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era, Reviews on Recent Clinical Trials, vol.9, issue.1, pp.1-7, 2014.
DOI : 10.2174/1574887108666131213120354

J. S. Au and P. J. Pockros, Novel Therapeutic Approaches for Hepatitis C, Clinical Pharmacology & Therapeutics, vol.54, issue.1, pp.78-88, 2014.
DOI : 10.1056/NEJMoa1214854

P. Gallay and K. Lin, Profile of alisporivir and its potential in the treatment of hepatitis C, Drug Design, Development and Therapy, vol.7, pp.105-115, 2013.
DOI : 10.2147/DDDT.S30946

R. Flisiak, J. Jaroszewicz, I. Flisiak, and T. ?api?ski, Update on alisporivir in treatment of viral hepatitis C, Expert Opinion on Investigational Drugs, vol.54, issue.1, pp.375-382, 2012.
DOI : 10.1016/S0168-8278(09)60097-0

R. Crabbé, An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C, Expert Opinion on Investigational Drugs, vol.365, issue.2, pp.211-220, 2009.
DOI : 10.1097/01.mcg.0000145494.76305.11

J. A. Garcia-rivera, Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir, Antimicrobial Agents and Chemotherapy, vol.56, issue.10, pp.5113-5121, 2012.
DOI : 10.1128/AAC.00919-12

R. Flisiak, The cyclophilin inhibitor Debio 025 combined with PEG IFN??2a significantly reduces viral load in treatment-na??ve hepatitis C patients, Hepatology, vol.75, issue.5, pp.1460-1468, 2009.
DOI : 10.1002/hep.22835

J. Guedj, L. Rong, H. Dahari, and A. S. Perelson, A perspective on modelling hepatitis C virus infection, Journal of Viral Hepatitis, vol.1, issue.7262, pp.825-833, 2010.
DOI : 10.1111/j.1365-2893.2010.01348.x

A. Chatterjee, P. F. Smith, and A. S. Perelson, Hepatitis C Viral Kinetics, Clinics in Liver Disease, vol.17, issue.1, pp.13-26, 2013.
DOI : 10.1016/j.cld.2012.09.003

A. Chatterjee, J. Guedj, and A. S. Perelson, Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?, Antiviral Therapy, vol.17, issue.6 Pt B, pp.1171-1182, 2012.
DOI : 10.3851/IMP2428

J. Guedj, Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life, Proceedings of the National Academy of Sciences, vol.110, issue.10, pp.3991-3996, 2013.
DOI : 10.1073/pnas.1203110110

J. Guedj, H. Dahari, R. T. Pohl, P. Ferenci, and A. S. Perelson, Understanding silibinin???s modes of action against HCV using viral kinetic modeling, Journal of Hepatology, vol.56, issue.5, pp.1019-1024, 2012.
DOI : 10.1016/j.jhep.2011.12.012

E. Shudo, R. M. Ribeiro, and A. S. Perelson, Modeling HCV kinetics under therapy using PK and PD information, Expert Opinion on Drug Metabolism & Toxicology, vol.243, issue.3, pp.321-332, 2009.
DOI : 10.1128/JVI.77.20.10769-10779.2003
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872514

M. Lindh, Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin, Journal of Viral Hepatitis, vol.55, issue.4, pp.82-89, 2013.
DOI : 10.1111/jvh.12014

U. Mihm, E. Herrmann, C. Sarrazin, and S. Zeuzem, Review article: predicting response in hepatitis C virus therapy, Alimentary Pharmacology and Therapeutics, vol.129, issue.1, pp.1043-1054, 2006.
DOI : 10.1136/gut.52.12.1784

T. H. Nguyen, J. Guedj, J. Yu, M. Levi, and F. Mentré, Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome, CPT: Pharmacometrics & Systems Pharmacology, vol.2, issue.7, p.56, 2013.
DOI : 10.1016/j.jhep.2011.01.050

V. Sypsa and A. Hatzakis, Modelling of viral dynamics in hepatitis B and hepatitis C clinical trials, Statistics in Medicine, vol.247, issue.2, pp.6505-6521, 2008.
DOI : 10.1002/sim.3457

C. Laouénan, Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients (ANRS CO20-CUPIC), Antimicrob. Agents Chemother, pp.2611-2625, 2014.

J. Guedj, Modeling viral kinetics and treatment outcome during alisporivir interferonfree treatment in HCV genotype 2/3 patients, 2014.

R. Flisiak, The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus, Hepatology, vol.42, issue.3, pp.817-826, 2008.
DOI : 10.1002/hep.22131

J. Lee, L. Zhang, A. Y. Men, L. A. Kenna, and S. Huang, CYP-Mediated Therapeutic Protein-Drug Interactions, Clinical Pharmacokinetics, vol.11, issue.5, pp.295-310, 2010.
DOI : 10.2165/11319980-000000000-00000

A. E. Aitken and E. T. Morgan, Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes, Drug Metabolism and Disposition, vol.35, issue.9, pp.1687-1693, 2007.
DOI : 10.1124/dmd.107.015511

M. Islam, Differential Effect of IFN?-2b on the Cytochrome P450 Enzyme System: A Potential Basis of IFN Toxicity and Its Modulation by Other Drugs, Clin. Cancer Res, vol.8, pp.2480-2487, 2002.

A. S. Flaman, C. Gravel, A. M. Hashem, M. Tocchi, and X. Li, The effect of interferon-?? on the expression of cytochrome P450 3A4 in human hepatoma cells, Toxicology and Applied Pharmacology, vol.253, issue.2, pp.130-136, 2011.
DOI : 10.1016/j.taap.2011.03.019

C. Chen, Y. Han, Z. Yang, and A. D. Rodrigues, Effect of interferon-??2b on the expression of various drug-metabolizing enzymes and transporters in co-cultures of freshly prepared human primary hepatocytes, Xenobiotica, vol.27, issue.6, pp.476-485, 2011.
DOI : 10.1074/jbc.R100033200

M. Vee, . Le, E. Jouan, A. Moreau, and O. Fardel, Regulation of drug transporter mRNA expression by interferon-?? in primary human hepatocytes, Fundamental & Clinical Pharmacology, vol.93, issue.1, pp.99-103, 2011.
DOI : 10.1111/j.1472-8206.2010.00822.x
URL : https://hal.archives-ouvertes.fr/hal-00680740

C. Fernandez, M. Buyse, M. German-fattal, and F. Gimenez, Influence of the proinflammatory cytokines on P-glycoprotein expression and functionality, J. Pharm. Pharm

J. Weiss, J. P. Becker, and W. Haefeli, Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro, International Journal of Antimicrobial Agents, vol.43, issue.2, pp.184-188, 2014.
DOI : 10.1016/j.ijantimicag.2013.10.003

V. Garg, R. S. Kauffman, M. Beaumont, and R. P. Heeswijk, Telaprevir: pharmacokinetics and drug interactions, Antiviral Therapy, vol.17, issue.7, pp.1211-1221, 2012.
DOI : 10.3851/IMP2356

N. Forestier, Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C, Hepatology, vol.127, issue.3, pp.640-648, 2007.
DOI : 10.1002/hep.21774

R. Bruno, Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study, Antivir. Ther, vol.9, pp.491-497, 2004.

J. M. Harris, N. E. Martin, and M. Modi, Pegylation, Clinical Pharmacokinetics, vol.26, issue.4, pp.539-551, 2001.
DOI : 10.2165/00003088-200140070-00005

H. Dahari, Pharmacodynamics of PEG-IFN-??-2a in HIV/HCV co-infected patients: Implications for treatment outcomes, Journal of Hepatology, vol.53, issue.3, pp.460-467, 2010.
DOI : 10.1016/j.jhep.2010.03.019

L. Zhang, S. L. Beal, and L. B. Sheiner, Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.6, pp.387-404, 2003.
DOI : 10.1023/B:JOPA.0000012998.04442.1f

E. Comets, K. Brendel, and F. Mentré, Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R, Computer Methods and Programs in Biomedicine, vol.90, issue.2, pp.154-166, 2008.
DOI : 10.1016/j.cmpb.2007.12.002
URL : https://hal.archives-ouvertes.fr/inserm-00274332

T. H. Nguyen, E. Comets, and F. Mentré, Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model, Journal of Pharmacokinetics and Pharmacodynamics, vol.13, issue.5, pp.499-518, 2012.
DOI : 10.1007/s10928-012-9264-2
URL : https://hal.archives-ouvertes.fr/inserm-00740912

F. Mentré and S. Escolano, Prediction Discrepancies for the Evaluation of Nonlinear Mixed-Effects Models, Journal of Pharmacokinetics and Pharmacodynamics, vol.30, issue.3, pp.345-367, 2006.
DOI : 10.1007/s10928-005-0016-4

J. Paeshuyse, The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replicationin vitro, Hepatology, vol.19, issue.4, pp.761-770, 2006.
DOI : 10.1002/hep.21102

A. U. Neumann, Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C Virus, The Journal of Infectious Diseases, vol.182, issue.1, pp.28-35, 2000.
DOI : 10.1086/315661

J. Medeiros-filho, Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy, World Journal of Gastroenterology, vol.12, issue.45
DOI : 10.3748/wjg.v12.i45.7271

J. Guedj, C. Bazzoli, A. U. Neumann, and F. Mentré, Design evaluation and optimization for models of hepatitis C viral dynamics, Statistics in Medicine, vol.38, issue.18, pp.1045-1056, 2011.
DOI : 10.1002/sim.4191
URL : https://hal.archives-ouvertes.fr/inserm-00615142

Y. Rotman, Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C, Gut, vol.50, issue.1, pp.161-169, 2014.
DOI : 10.1136/gutjnl-2012-303852

J. Pawlotsky, Antiviral action of ribavirin in chronic hepatitis C, Gastroenterology, vol.126, issue.3, pp.703-714, 2004.
DOI : 10.1053/j.gastro.2003.12.002

N. M. Dixit, J. E. Layden-almer, T. J. Layden, and A. S. Perelson, Modelling how ribavirin improves interferon response rates in hepatitis C virus infection, Nature, vol.23, issue.7019, pp.922-924, 2004.
DOI : 10.1086/315661

E. Snoeck, A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure, Clinical Pharmacology & Therapeutics, vol.308, issue.6, pp.706-713, 2010.
DOI : 10.1016/j.csda.2004.07.002
URL : https://hal.archives-ouvertes.fr/hal-00637434

J. Guedj, H. Dahari, E. Shudo, P. Smith, and A. S. Perelson, Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128), Hepatology, vol.376, issue.Suppl, pp.1030-1037, 2012.
DOI : 10.1002/hep.24788

T. Chou, Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies, Pharmacological Reviews, vol.58, issue.3, pp.621-681, 2006.
DOI : 10.1124/pr.58.3.10